Labcorp (LH) Tops Q2 EPS by 26c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Labcorp Announces 2022 Second Quarter Results
July 28, 2022 7:00 AM EDTCompany To Spin-Off Clinical Development Business
Revenue: Q2 of $3.7 billion versus $3.8 billion last year Diluted EPS: Q2 of $3.87 versus $4.76 last year Adjusted EPS: Q2 of $4.96 versus $6.13 last year Free Cash Flow: Q2 of $429 million versus $390 million last year Launched innovative diagnostics for skin cancer, neurodegenerative disease, fertility and COVID-19 Full-Year 2022 Guidance: Adjusted EPS raised to $19.00 to $21.25BURLINGTON, N.C.--(BUSINESS... More
